Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

USTC researchers created a groundbreaking on-chip photonic simulator, leveraging thin-film lithium niobate chips to simplify quantum simulations of complex structures, achieving high-dimensional synthetic dimensions with reduced frequency demands.

A research team led by Prof. Chuanfeng Li from the University of Science and Technology of China (USTC) has made a significant breakthrough in quantum photonics. The team successfully developed an on-chip photonic simulator capable of modeling arbitrary-range coupled frequency lattices with gauge potential. This achievement was detailed in a recent publication in Physical Review Letters.

<em>Physical Review Letters (PRL)</em> is a prestigious peer-reviewed scientific journal published by the American Physical Society. Launched in 1958, it is renowned for its swift publication of short reports on significant fundamental research in all fields of physics. PRL serves as a venue for researchers to quickly share groundbreaking and innovative findings that can potentially shift or enhance understanding in areas such as particle physics, quantum mechanics, relativity, and condensed matter physics. The journal is highly regarded in the scientific community for its rigorous peer review process and its focus on high-impact papers that often provide foundational insights within the field of physics.

Read more | >

Summary: Researchers have discovered a way to control human body temperature, mimicking the hibernation process of animals like bears. By manipulating the brain’s temperature regulation system, they can induce a state of “thermoregulatory inversion” (TI) in rats, reducing heat production even in cold environments.

This breakthrough could lead to controlled hypothermia in humans, improving survival rates in life-threatening situations like heart attacks and strokes. The discovery opens the door to therapeutic hypothermia, which can protect tissues from damage by lowering metabolism and oxygen demand.

Read more | >

While most humans can innately use their hands to communicate with others or grab and manipulate objects, many existing robotic systems only excel at simple manual tasks. In recent years, computer scientists worldwide have been developing machine learning-based models that can process images of humans completing manual tasks, using acquired information to improve robot manipulation, which could in turn enhance a robot’s interactions with both humans and objects in its surroundings.

Read more | >

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors—a type of immunotherapy—using only routine blood tests and clinical data.

The artificial intelligence–based model, dubbed SCORPIO, was developed by a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and the Tisch Cancer Institute at Mount Sinai.

The model is not only cheaper and more accessible, it’s significantly better at predicting outcomes than the two current biomarkers approved by the U.S. Food and Drug Administration (FDA), according to findings published in Nature Medicine.

Read more | >

Meta has appointed three new members to its board of directors, the company announced Monday: UFC president and CEO Dana White, European investment company Exor CEO John Elkann, and tech investor and entrepreneur Charlie Songhurst.

In a press release, Meta CEO Mark Zuckerberg said that White, Elkann, and Songhurst “will add a depth of expertise and perspective” that’ll help Meta “tackle the massive opportunities ahead with AI, wearables, and the future of human connection.”

White was named CEO of UFC in 2023, after the organization merged with WWE to form a new public company, TKO Group Holdings. He’s responsible for the overall strategic direction of UFC’s global business, including its live events series.

Read more | >

Predicting How Treatments Affect Individuals: A New Approach with PairNet.

Speakers: Cecile Tamura, Lokesh N, Riju Pahwa

Read more | >

BioViva focuses on translating this research into therapies.

In the search to extend human lifespan and address age-related diseases, telomerase reverse transcriptase (TERT) stands out as a promising focus of research. This enzyme, known for its role in maintaining telomeres—the protective caps at the ends of chromosomes—offers potential pathways to combat ageing at a cellular level. BioViva, under the leadership of CEO Liz Parrish, is working to transform telomerase-based scientific breakthroughs into tangible therapies aimed at enhancing health and longevity.

Read more | >